News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Post-Approval (Research/Post Marketing/Phase IV)
Pfizer (PFE) Pulls Plug on OTC Lipitor After Trial Failure 7/30/2015
Takeda (TKPYY) Announces Completion Of The Pioglitazone Post-Marketing Commitment And Submission Of Results To The European Medicines Agency, The European Medicines Agency And The PMDA 7/30/2015
AVANIR Pharmaceuticals (AVNR) Announces New Findings From Dementia/Alzheimer's Disease Cohort Of PRISM II Study At Alzheimer's Association International Conference 7/23/2015
Protein Sciences Corporation Release: New Clinical Study of Flublok Influenza Vaccine Shows That Groundbreaking Flublok Is More Effective Than The Traditional Flu Shot 6/25/2015
Egalet's Abuse-Deterrent, Extended-Release Morphine Demonstrates Bioequivalence At 60 Mg Dose 6/25/2015
Collegium (COLL) Announces Publication of "Comparing the Effect Of Tampering On The Oral Pharmacokinetic Profiles Of Two Extended-Release Oxycodone Formulations With Abuse-Deterrent Properties," In Pain Medicine 6/25/2015
Portola Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin Complex Concentrate Did Not 6/25/2015
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus XR Demonstrates Differentiated Pharmacokinetic Profile Compared To Twice-Daily Prograf Or Once-Daily Astagraf XL In Stable Kidney Transplant Patients 6/24/2015
MediciNova, Inc. Announces New Article Published On MN-166 (Ibudilast) In Addiction Biology 6/16/2015
Kyowa Hakko USA, Inc. Release: Combination Setria Glutathione And L-Citrulline Supplementation Proven To Increase Post-Exercise Benefits 6/15/2015
Vernalis PLC (VNLPY.PK) Announces CCP-07 Starts 12 Month Stability Testing 6/11/2015
Zealand Pharma  (ZEAL.CO) Informs Of Updates Given By Sanofi (SAN.PA) On Lyxumia And Lixilan On An IR Thematic Conference Call On Diabetes 6/9/2015
Zealand Pharma  (ZEAL.CO) Informs That Data Presented From The ELIXA Study Establish Lyxumia As The First GLP-1 Receptor Agonist With Cardiovascular Safety Proven In A Long-Term Outcome Trial 6/9/2015
New Data Show Superiority of Eli Lilly (LLY)'s Once-Weekly Trulicity (dulaglutide) to Lantus (insulin glargine) in Patients with Type 2 Diabetes 6/8/2015
Zealand Pharma  (ZEAL.CO) Announces That Sanofi (SAN.PA) Has Informed Of Results From Getgoal Duo-2, Showing Advantages Of Lyxumia Versus Rapid-Acting Insulin As Add-On To Lantus For The Treatment Of Type 2 Diabete 6/8/2015
Sanofi (SAN.PA) Announces Study Program Evaluating Toujeo In A Real-Life Setting 6/4/2015
Matinas BioPharma's MAT9001 Meets Primary And Secondary Endpoints In First Human Trial Versus Vascepa 6/1/2015
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Study Commences For Patients With Two Relapsed/Refractory Blood Cancers 5/28/2015
FDA Grants Fast Track Designation For IntelliPharmaCeutics Rexista Oxycodone XR Incorporating PODRAS Technology 5/26/2015
Astellas Pharma US Release: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 5/18/2015
AbbVie (ABBV) Receives Orphan Drug Designation For HUMIRA (Adalimumab) From The FDA For The Investigational Treatment Of Moderate-To-Severe Hidradenitis Suppurativa (HS) 5/15/2015
Orexigen (OREX) Aborts Required Study For Diet Drug Contrave 5/13/2015
Boehringer Ingelheim Release: First Patient Enrolled In Dabigatran Study Comparing Anticoagulation Strategies During AF Ablation 5/13/2015
Orexigen (OREX) Provides Statement On Termination Of The Light Study And Updates On Contrave Collaboration With Takeda Pharmaceuticals 5/13/2015
Heart-Stopping Morning Leads to Vertex (VRTX) Rise As FDA News Sees Positives 5/11/2015
Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation By The Hemispherx Biopharma (HEB) For Ampligen To Treat Patients With Ebola Virus Disease (EVD) 5/11/2015
Bristol-Myers Squibb (BMY) Release: Long-Term, 7-Year Study Of Nulojix (Belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction Of Death Or Graft Loss Over Cyclosporine Regimen In Kidney Transplant 5/6/2015
Kowa Pharmaceuticals America Release: New Meta-Analysis On Pitavastatin Demonstrates No Adverse Effect Compared With Placebo Or Other Statins On New-Onset Diabetes In Non-Diabetic Patients At Risk For Cardiovascular Disease 5/4/2015
Bayer HealthCare (BAY) Release: Five-Year Follow-Up Study Further Supports Effectiveness And Safety Of The Essure Procedure As A Non-Surgical, Non-Hormonal Option For Permanent Contraception 5/1/2015
Actavis (ACT) And Medicines360 Announce Publication Of ACCESS IUS Efficacy And Safety Study Of LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception 4/29/2015
Gilead (GILD) Offers Free Drugs in Georgia in Hep C Eradication Experiment 4/24/2015
Effect Of Genzyme (GENZ)’s Multiple Sclerosis Treatment Lemtrada (Alemtuzumab) On Slowing Brain Atrophy And MRI Lesion Activity Maintained Through Four Years 4/23/2015
Teva (TEVA) Presents Data Comparing Early Treatment With COPAXONE 40 Mg/Ml To Delayed Start Treatment At 67th American Academy of Neurology Annual Meeting In Washington, D.C. 4/23/2015
Biogen (BIIB) Release: TECFIDERA (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy For Newly-Diagnosed MS Patients 4/20/2015
Momenta Pharmaceuticals, Inc. (MNTA) Presents Key Glatopa (Glatiramer Acetate Injection) Data At American Academy of Neurology Annual Meeting 4/20/2015
AstraZeneca PLC (AZN)'s Diabetes Drug Onglyza May Increase Risk of Heart Failure, FDA Panel Reports 4/13/2015
Roche (RHHBY) Scientists Testing to See if Arthritis Blockbuster Will Work for Diabetes 4/10/2015
Deaths Review of Eli Lilly (LLY)'s Antipsychotic Zyprexa Relprevv "Inconclusive" 3/25/2015
Gilead (GILD) Warns After Nine Hepatitis Patients Taking Heart Drug Develop Condition, One Dies From Cardiac Arrest 3/25/2015
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion On Application For Orphan Designation By The European Medicines Agency Agency For Ampligen To Treat Patients With Ebola Virus Disease (EVD) 3/24/2015
Hemispherx Biopharma (HEB) To Present Data On The Activity Of Ampligen(R) Against The Ebola Virus 3/23/2015
Merz Aesthetics (Formerly Known as BioForm Medical, Inc.) Announces Primary Endpoint Met In Post-Market Clinical Study Of Xeomin (Incobotulinumtoxina) Vs. Botox® (Onabotulinumtoxina) For Glabellar Facial Lines 3/19/2015
Lundbeck Inc. (LUN.CO) Initiates Clinical Trial Evaluating Clobazam For Dravet Syndrome 3/17/2015
AstraZeneca PLC (AZN)'s Brilinta Proves Worthy Despite Higher Bleeding Risk 3/16/2015
Boehringer Ingelheim Release: Many Atrial Fibrillation Patients At High Risk Of Stroke Fail To Receive Guideline-Recommended Oral Anticoagulant Treatment 3/16/2015
Pfizer (PFE) Pain Med Lyrica Flunks Post Market Study in Adolescents 3/13/2015
Pfizer (PFE) Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA® Capsules CV As A Treatment For Adolescents With Fibromyalgia 3/13/2015
Trevi Therapeutics Announces Initiation Of A Pivotal Study Of Nalbuphine ER In Prurigo Nodularis 3/11/2015
Merck & Co. (MRK) Release: Two New Post-Hoc Analyses Of TRA 2°P TIMI 50 Study Showed ZONTIVITY (Vorapaxar) Added To Aspirin And/Or Clopidogrel Reduced Acute Limb Ischemia And Peripheral Revascularizations, Respectively, In Certain Patients With Peripheral Arterial Disease 3/5/2015
Genentech (RHHBY)'s Breast Cancer Cocktail Buys More Than a Year of Life 2/25/2015
Merck & Co. (MRK) Release: New Data From IMPROVE-IT Study Of VYTORIN® (Ezetimibe/Simvastatin) And TRA 2ºp TIMI 50 Study Of ZONTIVITY® (Vorapaxar) To Be Presented At American College of Cardiology Scientific Sessions 2/25/2015
Regeneron (REGN)'s Eylea Beats Genentech (RHHBY) in Rare Face Off Over Some Vision Loss Cases 2/20/2015
Celltrion Healthcare: Data Show The World’s First European Medicines Agency-Approved Biosimilar Monoclonal Antibody Remsima Could Reduce Cost Of Treating Crohn’s Disease By Up To €336 Million Over Five Years 2/20/2015
Novartis AG (NVS) May Already Have First True Anti-Aging Drug in Its Pipeline 2/19/2015
Regeneron (REGN) Release: NIH-Sponsored Comparative Effectiveness Trial In Diabetic Macular Edema Shows EYLEA (Aflibercept) Injection Demonstrated Significantly Greater Gains In Visual Acuity Than Both Bevacizumab And Ranibizumab 2/19/2015
Pfizer (PFE)'s Chantix Effective for Smokers 2/18/2015
New Study Vindicates Efficacy of Roche (RHHBY)'s Blockbuster Drug Tamiflu 2/2/2015
Cumberland Pharmaceuticals (CPIX) Release: Phase IV Studies Published Supporting The Safety Of A Shortened Infusion Time Of Caldolor® (ibuprofen) Injection 2/2/2015
AstraZeneca PLC (AZN)'s Brilinta Boosted by Major Clinical Trial Success 1/14/2015
Ipsen (IPN.PA) To Present Further Data On Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (Lanreotide), At Gastrointestinal Cancers Symposium 1/13/2015
DBV Technologies Announces Publication In The Journal Of Allergy And Clinical Immunology Of Data Demonstrating That Epicutaneous Immunotherapy May Influence The Natural History Of Allergy 1/12/2015
Merck & Co. (MRK)'s Gardasil Not Linked To Multiple Sclerosis, JAMA Reveals 1/7/2015
Cerulean Pharma Inc. (CERU) Announces Publication Describing Synergistic Anti-Tumor Activity Of CRLX101 With Avastin In Advanced Metastatic Ovarian Tumor Models 1/6/2015
Soligenix (SNGX) Announces Publication of Combination Ricin/Anthrax Vaccine Data 12/29/2014
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/23/2014
Genentech (RHHBY) Provides Update On Phase 3 MARIANNE Study In People With Previously Untreated Advanced HER2-Positive Breast Cancer 12/19/2014
FDA Breakthrough Status For Genentech (RHHBY)'s Lucentis 12/17/2014
Pfizer (PFE)'s Top Selling Drug Doesn't Help Patients With Lower Back Pain 12/15/2014
Merck & Co. (MRK)'s Keytruda Shrank Tumors In Hard-To-Treat Breast Cancer Patients 12/11/2014
Hemispherx Biopharma (HEB) Announces Data Showing Inhibition Of Ebola By Ampligen® Enlarged By Howard University Research 12/9/2014
Amgen (AMGN)'s Kyprolis Delivers In Phase 3 Multiple Myeloma Study 12/8/2014
Gilead Sciences, Inc. (GILD) Presents Follow-Up Data From Zydelig Registrational Studies In Patients With Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma 12/8/2014
Amgen (AMGN) And Onyx Pharmaceuticals, Inc. (ONXX) Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 12/8/2014
EXCLUSIVE: NHS Uses Ineffective IPF Therapy 12/5/2014
National Institute for Clinical Excellence (NICE) Requests More Info On Novartis AG (NVS)'s Xolair To Treat Chronic Hives 11/20/2014
Merck & Co. (MRK)'s Vytorin Proves Effective; IMPROVE-IT Trial Achieves Primary Endpoint 11/19/2014
Esperion Therapeutics, Inc. (ESPR) Climbs As CEO Lauds Merck & Co. (MRK)'s Zetia Data 11/19/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: Longer-term Outcome Data From The Largest Prospective Trial Of Soliris® (Eculizumab) In aHUS Underscore The Effectiveness Of Ongoing Soliris Treatment 11/17/2014
Confident Merck & Co. (MRK) Expects No Writedowns For Zetia, Vytorin Cholesterol Drugs 11/11/2014
Gilead Sciences, Inc. (GILD) Announces Harvoni Study Results In Chronic Hepatitis C Patients With Advanced Liver Disease And Those Who Failed Prior Treatment 11/11/2014
Teva Pharmaceutical Industries Limited (TEVA) Presents Positive Safety And Efficacy Data For QNASL® (Beclomethasone Dipropionate) Nasal Aerosol In Treating Children With Perennial Allergic Rhinitis 11/7/2014
FutureCeuticals Release: Human Clinical Study Indicates FruiteX-B® Calcium Fructoborate In Combination With Glucosamine And Chondroitin Provides Fast-Acting Joint And Flex Benefits 11/6/2014
AstraZeneca PLC (AZN)'s New Drug Olaparib May Also Work In Prostate Cancer 11/5/2014
MYOS (MYOS) Announces Positive Safety Data Demonstrating Fortetropin's™ Lack Of Adverse Effect On Serum Lipids And Cholesterol Levels 11/4/2014
Teva Pharmaceutical Industries Limited (TEVA) And Active Biotech AB (BTPC) Announce Expansion Of Laquinimod Clinical Development Program With New Trial In Primary Progressive Multiple Sclerosis And First Patient Screened In Huntington’s Disease Trial 11/4/2014
MediWound (MDWD) Initiates Post-Marketing Study With NexoBrid® To Treat Severe Burns In Pediatric Patients 11/3/2014
Boehringer Ingelheim GmbH Release: FDA Medicare Study In 134,000 Atrial Fibrillation Patients Confirms Positive Safety Profile And Effectiveness Of Pradaxa® In General Practice 11/3/2014
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S (LUN.CO) Release: Aripiprazole Once-Monthly Injectable Shows Superior Effectiveness To Paliperidone Palmitate Once-Monthly Injectable On Quality Of Life Scale In Patients With Schizophrenia 11/3/2014
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Report Results Of An Investigational Pilot Study Of Coadministration Of Lorcaserin Hcl And Phentermine Hcl 10/29/2014
Pfizer (PFE)’s PRISTIQ® (Desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction In Adults With Major Depressive Disorder 10/29/2014
Regeneron (REGN)'s EYLEA® Tops Rivals In Study 10/20/2014
Roche (RHHBY), Merck & Co. (MRK) Extend Immunotherapy Battle To Breast Cancer 10/17/2014
Celgene International Sárl (CELG) Release: Oral OTEZLA® (Apremilast) Data Presented At EADV Show Improved Measures Of Health-Related Quality Of Life And Work Productivity In Patients With Moderate To Severe Plaque Psoriasis 10/10/2014
Celgene International Sárl (CELG) Release: New Analyses Of Oral OTEZLA® (Apremilast) Presented At EADV Show Efficacy In Difficult-To-Treat Areas Of Moderate To Severe Plaque Psoriasis 10/10/2014
Vertex Pharmaceuticals (MA) (VRTX) Reviews Recent Progress And Announces Upcoming Milestones In The Development Of Multiple Combinations Of Medicines That Target The Underlying Cause Of Cystic Fibrosis 10/9/2014
Celgene International Sárl (CELG) To Present Long-Term Efficacy And Safety Data On Oral OTEZLA® (Apremilast) In Plaque Psoriasis And Psoriatic Arthritis At European Academy Of Dermatology And Venereology Congress 10/7/2014
Pfizer (PFE)'s Lung Cancer Drug Xalkori Effective In Rare Gene Trial 9/30/2014
Genentech (RHHBY)'s New Breast Cancer Drug Greatly Extends Survival Rates 9/30/2014
Synapse Biomedical Announces The Early Completion Of Enrollment In The FDA Post Approval Study For ALS Patients 9/30/2014
Janssen Pharmaceutical Inc. Release: ZYTIGA®* Plus Prednisone Demonstrates Statistically Significant Overall Survival In Men With Advanced Prostate Cancer Prior To Chemotherapy 9/29/2014
Daiichi Sankyo, Inc. (4568.t) Receives Approval For Additional Indications Of LIXIANA® (Edoxaban) In Japan 9/26/2014
Repros Therapeutics Inc. (RPRX) Release: Androxal® Second Pivotal Study Achieves Superiority In Top Line Analysis For Both Co-Primary Endpoints Versus Marketed Topical Gel In The Treatment Of Secondary Hypogonadism 9/26/2014
EPIRUS Biopharmaceuticals Announces Positive 58 Week Follow Up Data For BOW015 For Treatment Of Rheumatoid Arthritis 9/23/2014
Parenteral Drug Association Launches Effort To Harmonize Global Post-Approval Changes Protocols 9/22/2014
Zogenix, Inc. (ZGNX) Release: New Data Shows Zohydro® ER Reduced Pain And Improved Function In People With Chronic Pain 9/18/2014
Janssen-Cilag International NV (JNJ) Release: Results From Head-To-Head Studies Of INVOKANA® (Canagliflozin) Versus JANUVIA (Sitagliptin) Highlight The Importance Of Weight-Change On Quality Of Life And Cost Effectiveness Of Canagliflozin Among People With Type 2 Diabetes 9/17/2014
Vince & Associates Clinical Research Completes Enrollment Of Human Abuse Liability Study For Centanafadine For Adult ADHD 9/16/2014
Study Shows Novo Nordisk A/S (NVO)'s New Diabetes Drug Tresiba Effective And Safe For Children 9/16/2014
Astellas Pharma Inc. (ALPMY) Release: U.S. FDA Approves New Indication For The Use Of XTANDI® (enzalutamide) Capsules For Patients With Metastatic Castration-Resistant Prostate Cancer 9/11/2014
Teva Pharmaceutical Industries Limited (TEVA) Presents New Data Which Demonstrate Reduction Of Injection-Related Adverse Events With The Less Frequent Dosing Of Three-Times-A-Week COPAXONE® (Glatiramer Acetate Injection) 40 Mg Compared To Daily COPAXONE® 20 Mg 9/11/2014
Novartis AG (NVS): Rate Of Brain Shrinkage Faster In Multiple Schlerosis Patients 9/10/2014
Novaliq GmbH Announces Positive Results From Novatears® Observational Study In Mild To Moderate Evaporative Dry Eye Disease 9/10/2014
Sanofi Pasteur (SASY.PA) Release: FDA Approves Use Of Menactra® Vaccine For Booster Immunization Against Potentially Deadly Disease 9/9/2014
Amgen (AMGN), Servier Heart Drug Runs Into Safety Concerns In Major Clinical Study 9/4/2014
The International Myeloma Foundation Says Newly Published Study Confirms Survival Advantage With REVLIMID® And Further Advantages With Continuous Use In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Transplant 9/4/2014
Boehringer Ingelheim Corporation Release: European Society of Cardiology Congress 2014 Hot Line Session: Favourable Effect Of Pradaxa® On Kidney Function Over Time Compared To Warfarin 9/2/2014
Zogenix, Inc. (ZGNX) Release: Zohydro® ER Demonstrates Sustained 12-Hour Pain Relief 9/2/2014
Vifor Pharma Release: CONFIRM-HF Study Demonstrates That Injectafer® (Ferinject®) Improves Exercise Capacity In Patients With Chronic Heart Failure 9/2/2014
MediciNova, Inc. To Initiate Clinical Trial Of MN-166 (Ibudilast) In ALS 8/26/2014
Coherus Biosciences' Biosimilar Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study 8/15/2014
FDA Advisory Committee Recommends Approval Of Tiotropium Respimat® For The Maintenance Treatment Of COPD 8/15/2014
Sanofi Pasteur (SASY.PA) Touts Positive Trial Data For Fluzone High-Dose Vaccine 8/14/2014
Pfizer Inc. (PFE) Reports Top-Line Results From Two Placebo-Controlled Studies With Lyrica 8/13/2014
Scientists Retract Narcolepsy Study Linked To GlaxoSmithKline (GSK) Flu Vaccine 8/11/2014
Ampio Pharmaceuticals, Inc. (AMPE) Updates On Positive One-Month Results From Ampion Open Label Study 8/5/2014
Berlin Heart, Inc. Completes Enrollment In The EXCOR® Pediatric Ventricular Assist Device (VAD) Post Approval Study 8/4/2014
Hemispherx Biopharma (HEB)'s Two Drugs, Ampligen® And Alferon® Ranked Highly In Sensitivity Testing Against MERS/SARS Coronaviruses 8/4/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: European Commission Grants Orphan Drug Designation To Soliris® (Eculizumab) For The Treatment Of Patients With Myasthenia Gravis (MG) 8/1/2014
Study Claims Celgene (CELG) Drug Can Drive HIV Out Of Hiding 7/25/2014
CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In The Netherlands 7/21/2014
Shire Reports Results From Two Head-To-Head Studies Comparing Vyvanse® With Concerta® In ADHD Study 7/18/2014
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) Announce Enrollment Of First Patient In Phase IV EMANATE Trial To Assess Effectiveness And Safety Of Eliquis® (Apixaban) In Patients With NVAF Undergoing Cardioversion 7/17/2014
FDA Grants Astellas Qualified Infectious Disease Product Designation For Isavuconazole For The Treatment Of Invasive Candidiasis 7/16/2014
ACell, Inc. Initiates Post-Market Study Of MatriStem® Pelvic Floor Matrix 7/15/2014
Celgene (CELG)'s OTEZLA® Misses Mark In Phase 3 Spinal Arthritis Study 7/10/2014
Controversial Trial Discovers No Benefit For Expensive The Medicines Company (MDCO) Drug 7/9/2014
Merck & Co., Inc. (MRK)'s Gardasil HPV Vaccine Doesn't Increase Blood Clot Risk 7/9/2014
Merck & Co., Inc. (MRK)'s Januvia Linked To Increase In Heart Failure Hospitalizations 7/8/2014
Sunovion Pharmaceuticals Inc. Announces Data Published In The CHEST Journal From A One-Year, Large Simple Safety Study Evaluating BROVANA® (Arformoterol Tartrate) Inhalation Solution 7/8/2014
Roche (RHHBY) Finds "Serious Flaws" In Recent Study Doubting Tamiflu's Effectiveness 7/1/2014
FDA Grants Breakthrough Therapy Designation To Pradaxa® (Dabigatran Etexilate) Specific Investigational Antidote 6/30/2014
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014
InDex Pharmaceuticals AB Announces Results From COLLECT, A Clinical Trial Of Kappaproct® In The Treatment Of Moderate To Severe Ulcerative Colitis 6/27/2014
Pacira Pharmaceuticals, Inc. (PCRX) Announces Publication Of Pooled Results From IMPROVE Studies Evaluating Health Economic Benefits Of EXPAREL® 6/26/2014
ImpediMed Inc. Release: International Post-Approval Clinical Trial Commences Ahead Of Schedule 6/26/2014
H. Lundbeck A/S (LUN.CO) Release: New Study Results Demonstrate Brintellix® (Vortioxetine) Is Efficacious In Asian Patients Suffering From Depression 6/26/2014
Raptor Pharmaceutical Inc. (RPTP) Release: Data Published In Journal Of Pediatrics Demonstrated That PROCYSBI® Improved Quality Of Life And Preserved Kidney Function In Cystinosis Patients 6/24/2014
A 4-Week Hepatitis C Cure? Bristol-Myers Squibb Company (BMY) To Test Drugs With Gilead Sciences, Inc. (GILD)'s Sovaldi 6/23/2014
Chelsea Therapeutics, Inc. (CHTP) Release: NORTHERA™ Clinical Trial Data Published in Neurology 6/20/2014
Grafix® Manuscript From Osiris Therapeutics, Inc. (OSIR)’ Multi-Center, Randomized, Controlled Clinical Trial Accepted In Peer-Reviewed Journal 6/19/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: FDA Grants Orphan Drug Designation To Soliris® (Eculizumab) For The Treatment Of Patients With Myasthenia Gravis (MG) 6/17/2014
Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: Results Of A New Study Of Brintellix® (vortioxetine) vs. Escitalopram On Sexual Functioning In Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction 6/17/2014
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014
H. Lundbeck A/S (LUN.CO) Release: Brintellix® Demonstrated A Statistically Significantly Superior Improvement Compared To Escitalopram In Improving Sexual Functioning In Well Treated Patients Suffering From Depression And Experiencing Treatment-Emergent Sexual Dysfunction 6/17/2014
Hemispherx Biopharma (HEB) Announces New Publication With Potential Insight Into High Mortality Rate In Middle Eastern Respiratory Syndrome (MERS) 6/16/2014
H. Lundbeck A/S (LUN.CO) Release: New Study Shows That Brintellix® (Vortioxetine) Improves Cognitive Performance And Function In Adult Patients With Major Depression 6/16/2014
Chelsea Therapeutics, Inc. (CHTP) Presents Efficacy And Safety Data For NORTHERA At International Congress Of Parkinson's Disease And Movement Disorders 6/12/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
uniQure Announces Analysis Of Six-Year Follow-Up Data For Glybera® 6/3/2014
Boehringer Ingelheim Corporation Release: Antidote For Rapid Reversal Of Pradaxa® (Dabigatran Etexilate) Progresses Into Next Stage Of Clinical Investigation With Study In Patients 5/22/2014
The Medicines Company (MDCO) Release: Data On Angiox (Bivalirudin Injection) In Heart Attack Patients Presented At Europcr And Published In European Heart Journal 5/22/2014
GlaxoSmithKline (GSK) Touts Positive Incruse™-Ellipta®-Advair®-Diskus® Combo Data 5/20/2014
Dendreon Corporation (DNDN) Release: Treatment With PROVENGE® (Sipuleucel-T) Induces Antigen Spread Associated With Overall Survival Benefits In Advanced Prostate Cancer 5/20/2014
Biohit Release: Enrollment To Clinical Trials For Prevention Of Migraine-Type Headache 5/19/2014
Boehringer Ingelheim GmbH Release: New Study To Investigate Dabigatran Etexilate For Prevention Of Recurrent Stroke In High-Risk Patients 5/7/2014
Sucampo Pharmaceuticals, Inc. (SCMP) Announces New Data On AMITIZA And Opioid-Induced Constipation Published Online In Pain Medicine Journal 5/6/2014
Janssen Pharmaceutical Inc. Release: Landmark Study Shows Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (Paliperidone Palmitate) Significantly Delayed Time To Relapse In Patients With Schizophrenia Compared To Daily Oral Antipsychotics 5/5/2014
Kowa Pharmaceuticals America Release: Data Showed After 52 Weeks, LIVALO® (Pitavastatin) 4 Mg Maintained Similar Safety And Significantly Greater LDL-C Reduction Compared With Pravastatin 40 Mg In HIV-Infected Adults With Dyslipidemia 5/1/2014
Repros Therapeutics Inc. (RPRX) Release: FDA Recommends Sperm Endpoints As Key Parameters For Assessment Of Androxal® Versus Approved Topical Gel 5/1/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) Feels New Data Reinforce Efficacy Of TECFIDERA® (Dimethyl Fumarate) In MS Patients 4/30/2014
Biohit Starts Two Clinical Trials With Acetium® Capsule For Prevention Of Migraine-Type Headache 4/29/2014
Head-To-Head Study Reveals Novartis AG (NVS) Lung Drug Not Inferior To GlaxoSmithKline (GSK)'s Seretide 4/28/2014
AMAG Pharmaceuticals, Inc. (AMAG) Release: Study Showing Effectiveness Of Mugard® For Management Of Oral Mucositis Featured In The Journal Cancer 4/28/2014
Alexion Pharmaceuticals Inc. (ALXN) Initiates Multinational Registration Trials Of Eculizumab As A Potential Treatment For Patients With Relapsing Neuromyelitis Optica (NMO) And Refractory Generalized Myasthenia Gravis (MG) 4/24/2014
Cynapsus Therapeutics Announces Positive Results Of CTH-104 Clinical Study Of APL-130277 For Parkinson's Disease 4/24/2014
Saga Continues: Roche (RHHBY)'s Tamiflu No Better Than Tylenol At "Fighting Flu" 4/14/2014
Dendreon Corporation (DNDN) Release: Immune Responses Enhanced And Sustained When PROVENGE® (Sipuleucel-T) Is Given After Androgen Deprivation Therapy In Biochemically-Recurrent Prostate Cancer 4/11/2014
Gilead Sciences, Inc. (GILD)’s Sovaldi® Demonstrates Efficacy And Safety Among Chronic Hepatitis C Patients With Advanced Liver Disease 4/11/2014
FDA Grants Breakthrough Status Designation To Novartis AG (NVS)' Meningitis B Vaccine 4/8/2014
H. Lundbeck A/S (LUN.CO) Release: Treatment With Once-Monthly Abilify Maintena® (Aripiprazole) Significantly Reduces Hospitalisation Rates For Patients With Schizophrenia Compared With Daily Oral Antipsychotics 4/7/2014
Bristol-Myers Squibb Company (BMY)'s Eliquis® Works As Well As Pfizer Inc. (PFE)'s In Head-To-Head Subanalysis Study 3/27/2014
Roche (RHHBY)-Backed Study Finds Tamiflu Saved Lives In Flu Pandemic 3/19/2014
uniQure And Chiesi Farmaceutici SpA Announce Six Year Follow-up Data from Glybera® Treated Patients 3/17/2014
Pfizer Inc. (PFE) Vaccine Prevents Pneumonia In Landmark Study 3/14/2014
Merck & Co., Inc. (MRK) Release: New 96-Week ACTG Study Results Presented At CROI 2014; First Large Study Comparing ISENTRESS® (Raltegravir) Regimen To Two Protease Inhibitor Regimens In Previously Untreated Adults With HIV-1 3/5/2014
Janssen Pharmaceutica N.V. Release: New Data Show XEPLION® Significantly Delays Time To Relapse Compared To Treatment As Usual With Oral Antipsychotic Monotherapy 3/4/2014
Pfizer Inc. (PFE) Revs Up For Testing Of Over-The-Counter Lipitor 3/3/2014
Low-Level Usage Of Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Actos May Still Hold Bladder Cancer Risk: Study 2/28/2014
Baxter International, Inc. (BAX) Presents Data At EAHAD From Long-Term Outcomes Registry Reinforcing Prophylaxis Treatment Experience With ADVATE 2/27/2014
Pfizer Inc. (PFE) Touts Positive Results In Pneumonia Vaccine Post-Approval Study 2/24/2014
Roche (RHHBY) May Share Avastin Brain Cancer Data Amid Conflicting Results 2/21/2014
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) Release: In a Subanalysis, Eliquis® (apixaban) Reduced The Risk of Stroke And Demonstrated Fewer Major Bleeding Events Versus Warfarin Consistently Across Age Groups, Including Older Patients With Nonvalvular Atrial Fibrillation 2/21/2014
Innovus Pharma To Exhibit Zestra® Its Clinically Proven Product For Female Sexual Arousal And Desire At The International Society For The Study Of Women's Sexual Health 2014 Annual Meeting In San Diego 2/20/2014
AMAG Pharmaceuticals, Inc. (AMAG) Release: Study Shows Mugard® Is More Effective Than Sham-Control At Reducing Mouth And Throat Soreness Associated With Oral Mucositis In Head And Neck Cancer Patients 2/18/2014
Actelion Ltd. (ALIOF.PK)'s Lung Drug May Face Study Against Gilead Sciences, Inc. (GILD) Rival 2/12/2014
Repros Therapeutics Inc. (RPRX) Reports Findings From The Six Month Study Of Androxal® In Men With Secondary Hypogonadism 2/10/2014
Galderma Pharma S.A. Announces The Publication Of Positive Results Of The Long-Term Study Of Mirvaso® Gel For Treatment Of Persistent Erythema Of Rosacea 1/29/2014
Ranbaxy Laboratories (RANBAXY.BO) Workers Fudged Test Results: FDA 1/28/2014
FDA Approved 188 Drugs Using One Single Study As Evidence 1/23/2014
Teva Pharmaceutical Industries Limited (TEVA) Release: Data Demonstrates Key Genes Respond Differently To COPAXONE® (glatiramer acetate injection) Versus A Purported Generic Glatiramer Acetate 1/13/2014



//-->